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Case report - Transplantation
Giant left atrial thrombus 17 years after orthotopic heart
transplantation
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Abstract
We present the case of a 66-year-old woman who underwent orthotopic heart transplantation 17 years earlier for dilated cardiomyopathy.
After 7 years allograft coronary vasculopathy developed requiring coronary artery angioplasty. In year 15 postoperatively she experienced
congestive heart failure and she became symptomatic requiring diuretics and digoxin treatment. In year 16 postoperatively a routine
coronary computed tomography (CT) angiography study revealed a giant thrombus in the left atrium. The patient had had no thromboembolic-
related symptoms. Anticoagulation therapy was introduced and the patient has not presented any thromboembolic-related complication.
As the symptoms of cardiac insufficiency worsened we decided to evaluate the patient for re-transplantation.
 2010 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.
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1. Introduction
Since the first reported case in 1967 w1x, heart transplan-
tation has become the treatment of choice for patients
with end-stage heart failure. Traditionally, most orthotopic
heart transplants have been performed according to the
biatrial anastomotic technique developed and described by
Lower et al. w2x. Although biatrial anastomosis does not
require separate caval anastomoses, and therefore saves
time, potential problems include atrial dysfunction, sinus
node dysfunction, valvular insufficiency and thrombus
formation.
2. Case report
A 66-year-old woman underwent orthotopic heart trans-
plantation 17 years earlier for dilated cardiomyopathy. The
early postoperative period was uneventful. Immunosup-
pression included cyclosporine A, azathioprine and predni-
sone with corticoid therapy withdrawal after 24 months.
According to our protocol oral anti-platelet and cholesterol-
lowering therapy was instituted. Since year 7 postopera-
tively, despite a normal cardiac function, she presented
allograft coronary vasculopathy (CV) revealed by coronary
angiography, requiring percutaneous coronary artery angio-
plasty with stent insertion. As CV developed and M-TOR
inhibitor drugs became available, everolimus was intro-
duced and azathioprine was withdrawn. In year 15 postop-
eratively as the allograft CV progressed, the left ventricular
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ejection fraction began to diminish presenting NYHA func-
tional class III symptoms. Diuretics and digoxin therapy was
introduced, the patient responded well becoming less
symptomatic. In 2007, we started a clinical protocol to
follow-up transplanted patients, with a coronary CT angi-
ography performed annually. In October 2007, routine cor-
onary CT angiography found a dilated left atrium which
doubled the size of left ventricle with no other findings
(Fig. 1). Twelve months later (October 2008), a second
routine coronary CT angiography examination showed a
huge left atrial thrombus (Fig. 2); the patients had no
thromboembolic-related symptoms. Oral anticoagulant
therapy was introduced with acenocumarol to obtain an
International Normalized Ratio value between 2 and 2.5.
Six months after thrombus discovery, the patient has not
presented any thromboembolic-related complication. As
the symptoms of cardiac insufficiency worsened we decided
to evaluate the patient for re-transplantation.
3. Discussion
Atrial thrombus formation is a rare complication in trans-
planted recipients. Why did this patient present an intra-
cardiac thrombus 17 years after transplantation?
Virchow’s triad could explain the pathophysiology of
thrombus formation in this particular patient.
1. Abnormal blood flow: dilated cardiac chambers, poor
contractility and regional wall motion abnormalities may
predispose to thromboembolism by facilitating stasis of
intracardiac blood flow w3x. As we could see, the left
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Fig. 1. First coronary CT angiography. Comment: we observed a giant left
atrium that doubled the size of the left ventricle. Donor left atrium (D),
recipient left atrium (R).
Fig. 2. Second coronary CT angiography 12 months later. Comment: giant
intra-cardiac thrombus (arrow) on the roof of the left atrium occupying 1y3
of the cavity, mostly in the recipient’s left atrium (R), donor’s left atrium
(D).
atrium (as result of standard technique) almost doubled
the size of left ventricle. Although she was in sinus
rhythm, the dilated left atrium, certainly had blood
flow stasis.
2. Abnormalities in the blood vessels and endothelium:
evidence exists indicating that heart failure is often
accompanied by a hypercoagulable state and decreased
endothelium function w4, 5x. Reduction in levels of
endothelium-derived nitric oxide may promotes platelet
adhesion inducing in situ thrombosis indicated by the
fact that patients with heart failure have an increase
incidence of thromboembolic events – between 1.5 and
4% compared with 0.5% in patients without heart failure
w6, 7x.
3. Blood constituents: it has been demonstrated that
patients with heart failure, platelet function, rheology
and hemostatic markers are altered w4, 8, 9x.
In this particular case although the patient was under
anti-platelet therapy; the bigger atrial volumes and the
impaired atrial function in the standard technique, with its
consequent blood stasis, in conjunction with the fall in the
left ventricle ejection fraction may have played a role in
the thrombus formation. Treatment options include anti-
coagulation therapy or surgical exploration and thrombec-
tomy w10x. As for treatment options for this patient, surgical
exploration was avoided due to its high-risk, as the patient
had not presented any thromboembolic-related complica-
tion and a left atrial thrombus was discovered in a routine
examination, anticoagulation therapy was initiated and the
patient was included on the waiting list for a new cardiac
transplantation for re-transplantation.
PostScript: After submission of this article, unfortunately
the patients died on the waiting list for heart retransplan-
tation due to respiratory complications.
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